Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
CVS Health (NYSE: CVS) announced Friday that it has reduced employee bonuses due to lower-than-expected profits in 2024. The healthcare giant faced mounting costs, particularly from its Medicare plans, impacting overall financial performance.
A company spokesperson stated, “We did not meet our financial goals in 2024, and that’s reflected in our corporate bonus.”
CVS experienced a surge in Medicare enrollments, leading to increased expenses. The company also struggled with higher medical service utilization, a shift in quality ratings, and elevated costs from sicker Medicaid members. These factors contributed to financial setbacks, prompting executive changes and restructuring efforts.
In October, CVS replaced CEO Karen Lynch with longtime company executive David Joyner following investor pressure, including from activist Glenview Capital. Joyner has since initiated cost-cutting measures and appointed a new insurance head to stabilize operations.
Despite financial challenges, CVS recently exceeded Wall Street’s fourth-quarter profit expectations and provided an annual forecast aligning with analyst estimates. This signals potential improvement under the new leadership.
As CVS navigates economic headwinds, its strategic adjustments will be crucial in restoring growth and shareholder confidence.
